Navigation Links
BIDMC cardiovascular institute researchers will lead $4 million NIH grant to study micrornas
Date:8/16/2013

BOSTON A cardiovascular research team from Beth Israel Deaconess Medical Center (BIDMC) and Brigham and Women's Hospital (BWH), led by BIDMC Principal Investigator Saumya Das, MD, PhD, has been awarded a $4 million Common Fund grant from the National Institutes of Health (NIH) as part of a newly formed program on Extracellular RNA Communication. The five-year grant will focus on identifying microRNA biomarkers in heart disease.

Each year, complications from heart attacks (myocardial infarctions) contribute to more than half a million cases of heart failure and 300,000 cases of sudden cardiac arrest, when the heart suddenly stops. Both of these conditions are closely related to a process known as remodeling, in which the structure and function of the heart changes or remodels -- following a heart attack.

"Our goal is to explore the role that microRNAs play in predicting which heart-attack patients will go on to experience complications," explains Das, an electrophysiologist in BIDMC's Cardiovascular Institute and co-director of the cardiovascular genetics program within the Outpatient Cardiovascular Clinic.

"Current strategies used to identify the highest risk patients have often been inaccurate," he adds. "We think that a blood test that makes use of microRNA biomarkers could replace existing strategies and more accurately predict which patients might experience poor outcomes and thereby identify who would most benefit from frequent monitoring and medical care." Other investigators who are part of the NIH grant, "Plasma miRNA Predictors of Adverse Mechanical and Electrical Remodeling After Myocardial Infarction," include BIDMC Director of Cardiovascular Research Anthony Rosenzweig, MD, and BWH investigators Raymond Y. Kwong, MD, MPH, and Mark Sabatine, MD, MPH.

microRNAs are one type of extracellular RNA. Once considered nothing more than genomic "junk," microRNAs have more recently been recognized as playing a key role in cellular functions. Several years ago, scientists began to recognize that these small, noncoding RNAs were not only found inside cells, but could also be found in blood and other tissue fluids.

Using patient plasma samples from extensively characterized patients who have suffered heart attacks, the scientific team will first identify which specific microRNAs are related to poor heart remodeling. They will then use cell culture and animal models of heart disease to further prioritize which microRNAs play a functional role in disease progression. Finally, the investigators will validate these prioritized microRNAs as prognostic markers for poor health outcomes after heart attacks in a large prospective clinical trial.

"Ultimately, we think that miRNA-based tests could replace current tests to predict which patients might be at risk of complications and, therefore, be good candidates to receive an implanted defibrillator," says Das. "At the same time, we hope to be able to better predict which individuals are at less risk of complications and thereby spare them unnecessary and costly procedures."


'/>"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
Source:Eurekalert

Related biology news :

1. New research points to benefits of eggs, even for those at cardiovascular risk
2. Cell-permeable peptide shows promise for controlling cardiovascular disease
3. New therapy for heart failure may enhance bodys stem cell response at cardiovascular injury site
4. FASEB SRC announces conference registration open for: Neural Mechanisms in Cardiovascular Regulation
5. Bilirubin can prevent damage from cardiovascular disease
6. Daily multivitamin use does not reduce cardiovascular disease risk in men
7. Strawberries activate protection protein to prevent cardiovascular disease
8. Air pollution level changes in Beijing linked with biomarkers of cardiovascular disease
9. Tax on salt could reduce cardiovascular disease deaths by 3 percent
10. HUNT Biosciences and SomaLogic collaborate to validate protein biomarkers of cardiovascular risk
11. Minneapolis Heart Institute selected to participate in Cardiovascular Cell Therapy Research Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2020)... ... March 03, 2020 , ... Board-certified oral and maxillofacial surgeon, Dr. Michael ... years of training and experience, Dr. Noffze can successfully extract problem and impacted wisdom ... as possible is beneficial to the oral and overall health of most patients as ...
(Date:2/28/2020)... ... February 28, 2020 , ... Meridian Clinical Research , ... Industry Excellence (ViE) award for Best Clinical Trial Site. Meridian is also the ... Best Clinical Trial Network award. These nominations were the result of two voting rounds, ...
(Date:2/28/2020)... ... February 28, 2020 , ... Regen Suppliers is now offering ... available stem cell and exosome biologics. , Regen Suppliers offers an extensive variety ... adipose kits, PDO thread lifts and more. The company is truly a ...
Breaking Biology News(10 mins):
(Date:2/21/2020)... ... February 20, 2020 , ... ... to perform complex, efficient and elegant chemistry. Humans have been increasingly successful ... own goals. , Through rapidly evolving technologies and strategies for modern molecular ...
(Date:2/19/2020)... ... February 18, 2020 , ... Intech ... launch of a new and unified global brand identity, as it celebrates its ... engineering challenges, as well as an enthusiasm for designing and manufacturing state-of-the-art medical ...
(Date:2/10/2020)... ... ... R3 Medical Training announced it is now registering for its next Comprehensive ... hands on involving real patients and stem cell biologics, with every attendee receiving a ... Course has received rave reviews from attendees, who love the hands on nature of ...
(Date:1/28/2020)... FORT WORTH, Texas (PRWEB) , ... January 28, ... ... Midland Scientific to be the exclusive distributor to food and beverage manufactures ... years and are considered critical suppliers. This agreement will allow each company to ...
Breaking Biology Technology: